Literature DB >> 33089709

Carcinogenesis of Male Oral Submucous Fibrosis Alters Salivary Microbiomes.

M Y Chen1,2, J W Chen3, L W Wu4, K C Huang5, J Y Chen5, W S Wu6, W F Chiang7, C J Shih8, K N Tsai9, W T Hsieh9, Y H Ho9, T Y Wong2,5, J H Wu3, Y L Chen1,5.   

Abstract

Most oral squamous cell carcinoma (OSCC) tumors arise from oral premalignant lesions. Oral submucous fibrosis (OSF), usually occurring in male chewers of betel quid, is a premalignant stromal disease characterized by a high malignant transformation rate and high prevalence. Although a relationship between the inhabited microbiome and carcinogenesis has been proposed, no detailed information regarding the oral microbiome of patients with OSF exists; the changes of the salivary microbiome during cancer formation remain unclear. This study compared the salivary microbiomes of male patients with OSCC and a predisposing OSF background (OSCC-OSF group) and those with OSF only (OSF group). The results of high-throughput sequencing of the bacterial 16S rRNA gene indicated that OSF-related carcinogenesis and smoking status significantly contributed to phylogenetic composition variations in the salivary microbiome, leading to considerable reductions in species richness and phylogenetic diversity. The microbiome profile of OSF-related malignancy was associated with increased microbial stochastic fluctuation, which dominated the salivary microbiome assembly and caused species co-occurrence network collapse. Artificial intelligence selection algorithms consistently identified 5 key species in the OSCC-OSF group: Porphyromonas catoniae, Prevotella multisaccharivorax, Prevotella sp. HMT-300, Mitsuokella sp. HMT-131, and Treponema sp. HMT-927. Robust accuracy in predicting oral carcinogenesis was obtained with our exploratory and validation data sets. In functional analysis, the microbiome of the OSCC-OSF group had greater potential for S-adenosyl-l-methionine and norspermidine synthesis but lower potential for l-ornithine and pyrimidine deoxyribonucleotide synthesis and formaldehyde metabolism. These findings indicated that the salivary microbiome plays important roles in modulating microbial metabolites during oral carcinogenesis. In conclusion, our results provided new insights into salivary microbiome alterations during the malignant transformation of OSF.

Entities:  

Keywords:  biomarker; dysbiosis; machine learning; microbiota; precancerous conditions; saliva

Year:  2020        PMID: 33089709     DOI: 10.1177/0022034520968750

Source DB:  PubMed          Journal:  J Dent Res        ISSN: 0022-0345            Impact factor:   6.116


  5 in total

1.  Betel quid chewing and oral potential malignant disorders and the impact of smoking and drinking: A meta-analysis.

Authors:  Hui-Jun Lin; Xiao-Lei Wang; Meng-Yuan Tian; Xing-Li Li; Hong-Zhuan Tan
Journal:  World J Clin Cases       Date:  2022-04-06       Impact factor: 1.534

Review 2.  The contribution of artificial intelligence to reducing the diagnostic delay in oral cancer.

Authors:  Betul Ilhan; Pelin Guneri; Petra Wilder-Smith
Journal:  Oral Oncol       Date:  2021-03-09       Impact factor: 5.337

Review 3.  Oral microbiota in human systematic diseases.

Authors:  Xian Peng; Lei Cheng; Yong You; Chengwei Tang; Biao Ren; Yuqing Li; Xin Xu; Xuedong Zhou
Journal:  Int J Oral Sci       Date:  2022-03-02       Impact factor: 24.897

4.  Identification of a BRAF/PA28γ/MEK1 signaling axis and its role in epithelial-mesenchymal transition in oral submucous fibrosis.

Authors:  Changqing Xie; Zaiye Li; Yufei Hua; Silu Sun; Liang Zhong; Qian Chen; Hui Feng; Ning Ji; Taiwen Li; Xikun Zhou; Xin Zeng; Zhangui Tang; Chongkui Sun; Jing Li; Qianming Chen
Journal:  Cell Death Dis       Date:  2022-08-12       Impact factor: 9.685

5.  Microbiome dysbiosis inhibits carcinogen-induced murine oral tumorigenesis.

Authors:  Yuh-Ling Chen; Kuan-Chih Huang; Jer-Horng Wu; Tsunglin Liu; Jiung-Wen Chen; Jia-Yan Xie; Meng-Yen Chen; Li-Wha Wu; Chun-Liang Tung
Journal:  J Cancer       Date:  2022-08-08       Impact factor: 4.478

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.